18th Feb 2015 08:21
LONDON (Alliance News) - Clinigen Group PLC said that its Global Access Programs arm will be managing a programme to provide patients with access to Raptor Pharmaceuticals Corp's Procysbi treatment for nephropathic cystinosis.
This program will make the treatment available worldwide, except in the US where it is already commercial available, Latin America and a small number of European territories.
Clinigen's Global Access Programs arm develops and implements global access programs for biotechnology and pharmaceutical companies seeking to sell unlicensed, licensed and end-of-life cycle products.
Nephropathic cystinosis is a condition beginning in infancy which causes poor growth and a type of kidney damage, caused by a build of of cystine.
"We are very proud that Raptor have selected Clinigen GAP as their partner to manage this global access program," said Senior Vice President of Clinigen's GAP arm Mark Corbett in a statement.
"We are able to utilize our extensive international expertise in project management, regulatory advice and logistics in order to ensure Raptor can effectively address this area of unmet medical need," Corbett said.
Shares in Clinigen are trading down 0.5% at 536.94 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L